Hazer Group Limited

HZR

Hazer Group Ltd. engages in the research and development of novel graphite, and hydrogen production technology. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-12-02. The Company’s process enables the conversion of natural gas and similar feedstocks, into hydrogen and graphite, using iron ore as a process catalyst. Its Hazer Process focuses on savings for the hydrogen producer, as well as providing clean hydrogen with lower carbon dioxide emissions, enabling such hydrogen to be used in a range of developing clean energy applications, as well as in existing chemical processing industries. The HAZER Process produces synthetic graphite. The firm's markets include industrial hydrogen, hydrogen mobility and synthetic graphite. The company also has facilities, including a research and development lab and a fluid bed reactor pilot plant.

Adalta Limited

1AD

AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The company is headquartered in Melbourne, Victoria. The company went IPO on 2016-08-22. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies.

Anson Resources Limited

ASN

Anson Resources Ltd. is an exploration company, which engages in iron sand mining activities. The company is headquartered in Perth, Western Australia. The company went IPO on 2010-07-08. The firm is focused on the discovery, acquisition and development of natural resources for energy and technology markets. The Company’s projects include Paradox Basin Lithium Project, WA Project Portfolio and Yellow Cat Uranium-Vanadium Project. The Paradox Basin Brine is a lithium brine project, located in Utah, United States. The project covers a total area of approximately 95 square kilometers (km2). The firm has an approximately 458 km2 tenement portfolio for base metals in Yilgarn Craton, Western Australia, including the Bull project (82km2), Ajana/Mary Springs project (222km2) and Hooley Well project (154km2). The Yellow Cat Project is located in the Thompson District, Grand County, Utah and comprises 85 Lodclaimsim. The project is an approximately 708 hectares exploration package with high-grade uranium-vanadium production and exploration.

Archer Materials Limited

AXE

Archer Materials Ltd. is a materials technology company developing advanced semiconductor devices and processor chips related to quantum computing and medical diagnostics in Australia. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-08-14. The firm is developing advanced semiconductor devices, including chips relevant to quantum computing and medical diagnostics. The firm is progressing the development of its 12CQ quantum computing qubit processor chip (12CQ chip) and lab-on-a-chip biochip technology (biochip). The 12CQ chip is utilizing a carbon-based architecture that has the potential for practical qubit processing. The company is focused on advancing its 12CQ chip technology towards integration with mobile devices. Its biochip development involves integrating graphene with miniaturized lab-on-a-chip platforms for advanced medical diagnostics. The company is designing and building its biochip in clean-room facilities and engineering materials at the atom-scale. The company also develops its biochip for digitizing biologically relevant signals like those from viruses or bacteria.

ESGI

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.